Production (Stage)
Claritas Pharmaceuticals, Inc.
CLAZF
$0.00
$0.000.00%
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Net Income | 143.83% | 77.57% | -116.50% | 92.29% | 57.68% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.77% | -86.88% | 118.63% | -97.65% | 215.68% |
| Change in Net Operating Assets | 4.65% | 4,052.17% | -2,353.57% | -103.30% | -170.64% |
| Cash from Operations | -205.24% | 306.06% | -1,146.15% | -212.26% | 123.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 87.50% | 100.00% |
| Cash from Investing | -- | -- | -- | 87.50% | 100.00% |
| Total Debt Issued | -- | 73.53% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.53% | -- | -- | -100.00% | -38.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.53% | 73.53% | -- | -100.00% | -57.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.46% | 3,075.00% | 179.31% | -48,600.00% | 160.56% |